Amgen sees 26% jump in R&D spending

While many drugmakers are trying to keep a lid on R&Dexpenses, Amgen reported today in its quarterly earnings that its R&D costs increased 26% to $808 million in order to fund late-stage clinical trials. The biotech giant ($AMGN) now has 10 programs in Phase III development, including studies for the cancer drugs ganitumab and AMG 386, according to the firm's website. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.